Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) Return on Equity (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Return on Equity for 6 consecutive years, with 0.53% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Equity fell 28.0% to 0.53% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.53%, a 28.0% decrease, with the full-year FY2024 number at 0.39%, down 2.0% from a year prior.
  • Return on Equity was 0.53% for Q3 2025 at 4D Molecular Therapeutics, down from 0.44% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.18% in Q2 2024 to a low of 0.53% in Q3 2025.
  • A 5-year average of 0.33% and a median of 0.3% in 2024 define the central range for Return on Equity.
  • Biggest YoY gain for Return on Equity was 49bps in 2021; the steepest drop was -64bps in 2021.
  • 4D Molecular Therapeutics' Return on Equity stood at 0.26% in 2021, then tumbled by -70bps to 0.45% in 2022, then increased by 29bps to 0.32% in 2023, then increased by 4bps to 0.3% in 2024, then tumbled by -75bps to 0.53% in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Return on Equity are 0.53% (Q3 2025), 0.44% (Q2 2025), and 0.36% (Q1 2025).